Voulgarelis, M <br/><br/>
Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Aug 2004 
 - 1050-3 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1462-0324 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keh248  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD--analysis<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>B-Lymphocytes--immunology<br/>Cryoglobulinemia--etiology<br/>Cyclophosphamide--adverse effects<br/>Doxorubicin--adverse effects<br/>Drug Therapy, Combination<br/>Humans<br/>Lymphoma, B-Cell--drug therapy<br/>Middle Aged<br/>Prednisone--adverse effects<br/>Rituximab<br/>Sjogren's Syndrome--complications<br/>Treatment Outcome<br/>Vincristine--adverse effects